Literature DB >> 29634418

Demethylation of GFRA4 Promotes Cell Proliferation and Invasion in Hirschsprung Disease.

Gang Wang1, Lijuan Zhang1, Hefeng Wang1, Mingyu Cui1, Wei Liu1, Yang Liu1, Xiangyu Wu1.   

Abstract

Hirschsprung disease (HSCR) is congenital intestinal aganglionosis attributed to a failure to migrate and survive of neural crest-derived cells. Glial cell-derived neurotrophic factor alpha 4 (GFRA4) is expressed in the derivatives of the neural crest in the enteric nervous system, but whether it is related with HSCR still remains unclear. This study was designed to investigate its role and epigenetic mechanisms in HSCR in vitro. The expression of GFRA4 mRNA in HSCR tissues was determined using quantitative real-time PCR analysis. In this study, we found that GFRA4 expression was significantly reduced in HSCR tissues and cells through GFRA4 methylation by quantitative real-time PCR analysis, methylation-specific PCR, and bisulfite sequencing PCR. DNA methyltransferase inhibitor, 5-AzaC, concomitantly upregulated the protein levels of GFRA4, as well as DNA methyltransferase1 (DNMT1) and DNMT2 in SH-5YSY cells. Moreover, we found upregulated GFRA4 significantly promoted cell proliferation, cell cycle progression and invasion, but inhibited apoptosis in SH-5YSY cells, whereas GFRA4 knockdown caused the opposite effects in SH-5YSY cells by CCK-8, 5-ethynyl-2'-deoxyuridine (EdU), flow cytometry, and Transwell assays. In conclusion, our results support that aberrant CpG hypermethylation at least partly accounts for GFRA4 silencing in HSCR, which impairs its protective role in enteric nervous system.

Entities:  

Keywords:  CpG hypermethylation; Hirschsprung disease; cell proliferation; glial cell-derived neurotrophic factor alpha 4; invasion

Mesh:

Substances:

Year:  2018        PMID: 29634418     DOI: 10.1089/dna.2017.3928

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

Review 1.  Peptides as epigenetic modulators: therapeutic implications.

Authors:  Yorick Janssens; Evelien Wynendaele; Wim Vanden Berghe; Bart De Spiegeleer
Journal:  Clin Epigenetics       Date:  2019-07-12       Impact factor: 6.551

Review 2.  "Too much guts and not enough brains": (epi)genetic mechanisms and future therapies of Hirschsprung disease - a review.

Authors:  Emilie G Jaroy; Lourdes Acosta-Jimenez; Ryo Hotta; Allan M Goldstein; Ragnhild Emblem; Arne Klungland; Rune Ougland
Journal:  Clin Epigenetics       Date:  2019-09-13       Impact factor: 6.551

3.  Genome-wide analysis of DNA methylation in Hirschsprung enteric precursor cells: unraveling the epigenetic landscape of enteric nervous system development.

Authors:  Leticia Villalba-Benito; Daniel López-López; Ana Torroglosa; Carlos S Casimiro-Soriguer; Berta Luzón-Toro; Raquel María Fernández; María José Moya-Jiménez; Guillermo Antiñolo; Joaquín Dopazo; Salud Borrego
Journal:  Clin Epigenetics       Date:  2021-03-09       Impact factor: 6.551

4.  Multi-Omics Analysis Reveals Changes in the Intestinal Microbiome, Transcriptome, and Methylome in a Rat Model of Chronic Non-bacterial Prostatitis: Indications for the Existence of the Gut-Prostate Axis.

Authors:  Junsheng Liu; Yihe Wang; Guangwen Zhang; Liu Liu; Xichun Peng
Journal:  Front Physiol       Date:  2022-01-11       Impact factor: 4.566

5.  Association between miR-492 rs2289030 G>C and susceptibility to Hirschsprung disease in southern Chinese children.

Authors:  Yi Zheng; Yanqing Liu; Mi Wang; Qiuming He; Xiaoli Xie; Lifeng Lu; Wei Zhong
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

6.  Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4.

Authors:  Vijay G Bhoj; Lucy Li; Kalpana Parvathaneni; Zheng Zhang; Stephen Kacir; Dimitrios Arhontoulis; Kenneth Zhou; Bevin McGettigan-Croce; Selene Nunez-Cruz; Gayathri Gulendran; Alina C Boesteanu; Laura Johnson; Michael D Feldman; Enrico Radaelli; Keith Mansfield; MacLean Nasrallah; Rebecca S Goydel; Haiyong Peng; Christoph Rader; Michael C Milone; Don L Siegel
Journal:  Mol Ther Oncolytics       Date:  2021-01-26       Impact factor: 7.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.